image credit: Adobe Stock

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

March 9, 2023


The partnership will see both companies advance MDX-2201 to an Investigational New Drug application filing, after which Merck will be responsible for clinical and regulatory activities, as well as product commercialisation.

In exchange, Opko will receive an upfront payment of $50m and will be eligible for milestone payments of up to $872.5m plus royalties on global sales.

There are currently no FDA approved vaccines or treatments for EBV, a common virus which infects most people at some point during their lives.

Read More on PMLiVE